Portfolio companies news

08 December 2014

miraDry Winner of the 2014 Pinnell Award for Product Innovation” - UK Aesthetic Awards 2014

Winner of the 2014 Pinnell Award for Product Innovation, miraDry uses precisely controlled electromagnetic energy to significantly reduce underarm sweat. The judging panel were particularly impressed by the consistent results it has achieved for over 20,000 patients. 

06 December 2014

Tragara Reports Interim Results of Phase 1b Study of TG02 and Carfilzomib in Multiple Myeloma

TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy.

01 December 2014

Neothetics Announces Closing of Upsized Initial Public Offering

Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the closing of its initial public offering of 4,650,000 shares of its common stock at an initial public offering price of $14.00 per share. The company originally filed to raise 4,300,000 shares. 

24 November 2014

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2014 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today provided a business update and announced its financial results for the third quarter ended September 30, 2014.

18 November 2014

Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies at the 26th EORTC-NCI-AACR Symposium

Epic Sciences will present data describing the detection of clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood. The poster presentation will take place on November 20 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. 

13 November 2014

Epic Sciences Appoints Toni Wayne as Vice President of Human Resources

Strategic leader in aligning human resources management with business objectives and operations joins Epic's fast-paced, rapid-growth team.

12 November 2014

Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Because tumor biopsy material is often limited in lung cancer patients, Epic developed a new assay that detects PD-L1 protein on CTCs in a blood sample. 

21 October 2014

Epic Sciences Appoints Michael Giske as Chief Information Officer

Epic Sciences announced the appointment of Michael Giske as chief information officer. Mr. Giske has more than 25 years of defining, designing and implementing secure, global, large-scale technology solutions to deliver innovative and impactful products. At Epic, he will lead the IT strategy and execution for the company’s diagnostics platform, which includes Epic’s circulating tumor cell (CTC) technology. 

15 October 2014

Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis. In the phase 1/2 clinical study, eight patients diagnosed with non-infectious uveitis at three U.S. study centers received a single suprachoroidal injection of a formulation of preservative-free triamcinolone acetonide injectable suspension using Clearside’s proprietary microinjector. 

15 September 2014

Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

Epic Sciences announced today the appointment of Glen Paul Freiberg, RAC as vice president of regulatory affairs and quality assurance. Mr. Freiberg has more than 35 years of FDA-related experience and is recognized as a key leader in successful regulatory and compliance strategies for diagnostic products. Epic’s circulating tumor cell (CTC) technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy, selection and early drug resistance detection to improve the treatment of cancer.